VEGFA and nonpapillary renal cell carcinoma: The CARMENA trial is the only randomized controlled trial investigating the efficacy of nephrectomy in patients with metastatic ccRCC receiving anti-vascular endothelial growth factor (anti-VEGF) therapy [12].